{"id":24085,"date":"2026-03-15T15:07:27","date_gmt":"2026-03-15T15:07:27","guid":{"rendered":"https:\/\/readtrends.com\/en\/car-t-ms-trial\/"},"modified":"2026-03-15T15:07:27","modified_gmt":"2026-03-15T15:07:27","slug":"car-t-ms-trial","status":"publish","type":"post","link":"https:\/\/readtrends.com\/en\/car-t-ms-trial\/","title":{"rendered":"Can a groundbreaking cancer therapy help people with multiple sclerosis?"},"content":{"rendered":"
\n

Lead:<\/strong> A small, early-stage trial at the Cleveland Clinic is testing whether CAR-T \u2014 a cancer immunotherapy that reprograms a patient\u2019s T cells \u2014 can curb multiple sclerosis (MS) by eliminating overactive B cells. The trial enrolled four people with MS and began infusions between six and 12 months ago; participant Grace Miller received her infusion last May. Miller, now 46 and living in Fishers, Indiana, says she has begun to take more steps without a cane but clinicians caution it is too soon to call the treatment effective. Researchers emphasize these are exploratory studies and note meaningful risks including cytokine release syndrome and neurotoxicity.<\/p>\n

Key Takeaways<\/h2>\n
    \n
  • CAR-T therapy, successful in B cell cancers like leukemia and lymphoma, is being repurposed to target dysregulated B cells implicated in MS progression.<\/li>\n
  • The Cleveland Clinic trial has treated four people with MS (two with progressive MS, two with relapsing MS); all received a single CAR-T infusion 6\u201312 months ago.<\/li>\n
  • One participant, Grace Miller, who received her infusion last May, reports some functional gains (e.g., picking up an 18-month-old child while standing) but still uses a cane 10 months after treatment.<\/li>\n
  • Trials at Stanford, Massachusetts General, and Columbia are underway; the Cleveland study is sponsored by Bristol Myers Squibb.<\/li>\n
  • Potential benefits hinge on CAR-T\u2019s ability to reach B cells behind the blood\u2013brain barrier \u2014 a limitation of existing antibody therapies \u2014 but long-term efficacy and safety remain unproven.<\/li>\n
  • Known severe risks include cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS); these risks may present differently in people with MS than in cancer patients.<\/li>\n
  • Experts are divided: some see promise in preventing further inflammation, while others caution CAR-T is unlikely to repair established neurodegeneration without adjunctive regenerative therapies.<\/li>\n<\/ul>\n

    Background<\/h2>\n

    CAR-T (chimeric antigen receptor T cell) therapy rewires a patient\u2019s own T cells to recognize and kill cells bearing a targeted protein. In oncology, CAR-T has shown dramatic remissions in certain B cell leukemias and lymphomas, prompting interest in autoimmune diseases driven by aberrant B cells. Multiple sclerosis is a chronic autoimmune disorder in which immune cells, including B cells, attack myelin \u2014 the insulating layer around nerve fibers \u2014 leading to slowed or blocked nerve signaling and progressive disability.<\/p>\n

    Existing MS therapies include monoclonal antibodies that deplete B cells in the bloodstream; however, many of these agents do not efficiently cross the blood\u2013brain barrier to reach B cells residing within the central nervous system. That reservoir of brain-embedded B cells is suspected to contribute to disease progression, particularly in progressive MS, where inflammatory lesion formation becomes less prominent and neurodegeneration grows more central to disability.<\/p>\n

    Because CAR-T involves a one-time infusion after lymphodepleting chemotherapy, investigators hope it may produce durable B cell suppression, potentially reducing the need for repeated treatments. Yet the approach is novel in noncancer patients, and MS cohorts differ clinically and immunologically from oncology populations, complicating safety and efficacy predictions.<\/p>\n

    Main Event<\/h2>\n

    Last year the Cleveland Clinic launched an early-phase CAR-T trial enrolling people with MS and another autoimmune condition, myasthenia gravis. The study \u2014 sponsored by Bristol Myers Squibb \u2014 has treated four people with MS and three with myasthenia gravis. All four MS participants received their modified cells between six and 12 months prior to reporting, with Miller\u2019s infusion administered last May.<\/p>\n

    Miller\u2019s history typifies many with longstanding MS: first diagnosed at 24 after years of unexplained fatigue and episodic neurological symptoms, she spent 15 years on two medications that caused frequent adverse effects and left her increasingly limited in vision and mobility. After the CAR-T infusion she reports incremental functional improvements but clinicians say validated recovery metrics and longer follow-up are needed before drawing conclusions.<\/p>\n

    Investigators describe the treatment sequence as follows: T cells are collected, genetically modified to target B cells, and then reinfused after a short course of chemotherapy to create space for engraftment. The single-infusion design contrasts with chronic antibody therapies and raises the possibility of prolonged B cell depletion with one intervention, but also concentrates risk into a compact timeline when inflammatory complications are most likely.<\/p>\n

    Across other centers, groups at Stanford, Massachusetts General Hospital and Columbia University have initiated similar exploratory trials, reflecting broad scientific interest. Enrollment numbers and participant characteristics vary by protocol; all are early-stage and aimed primarily at safety and immune-target engagement rather than definitive efficacy.<\/p>\n

    Analysis & Implications<\/h2>\n

    Biologically, CAR-T may offer an advantage if modified T cells can cross into the central nervous system and eliminate pathogenic B cells sheltered behind the blood\u2013brain barrier. Preclinical and clinical oncology experience provides a technical foundation, but MS poses unique challenges: the disease combines inflammatory activity with irreversible neurodegeneration, especially in progressive forms.<\/p>\n

    Clinicians who are skeptical argue that reducing inflammation alone may not recover lost neural tissue or restore function once substantial degeneration has occurred. Several experts in MS care emphasize the need for regenerative strategies \u2014 for example, therapies that promote remyelination or neuronal repair \u2014 alongside immune modulation to achieve meaningful recovery for many patients.<\/p>\n

    From a safety perspective, CAR-T side effects such as CRS and ICANS are well characterized in cancer patients, yet their incidence and severity in people with autoimmune disorders remain uncertain. MS patients\u2019 baseline central nervous system inflammation could theoretically increase susceptibility to neurotoxic events, making careful monitoring and conservative trial design essential.<\/p>\n

    Economically and logistically, single-infusion cellular therapies present a different model from repeat-dose biologics: if proven safe and durable, CAR-T could reduce lifetime treatment costs and adherence burdens. However, current manufacturing complexity, high upfront costs, and the need for specialized centers are major barriers to broad accessibility in the near term.<\/p>\n

    Comparison & Data<\/h2>\n
    \n\n\n\n\n\n\n\n\n
    Trial Site<\/th>\nMS Participants<\/th>\nInfusion Timing<\/th>\nSponsor \/ Status<\/th>\n<\/tr>\n<\/thead>\n
    Cleveland Clinic<\/td>\n4 (2 progressive, 2 relapsing)<\/td>\n6\u201312 months ago; one infusion (Miller: last May)<\/td>\nBristol Myers Squibb \/ Early-stage<\/td>\n<\/tr>\n
    Stanford University<\/td>\nNot publicly specified<\/td>\nEarly-stage<\/td>\nAcademic \/ Exploratory<\/td>\n<\/tr>\n
    Massachusetts General<\/td>\nNot publicly specified<\/td>\nEarly-stage<\/td>\nAcademic \/ Exploratory<\/td>\n<\/tr>\n
    Columbia University<\/td>\nNot publicly specified<\/td>\nEarly-stage<\/td>\nAcademic \/ Exploratory<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

    The table summarizes public information from trial announcements and reporting: the Cleveland Clinic cohort is the most detailed publicly, with four MS participants and infusion windows described as 6\u201312 months prior. Other academic centers have announced similar studies but have not released comparable participant-level detail. These trials are primarily designed to measure safety and biological effects on B cell populations rather than to provide definitive clinical outcomes.<\/p>\n

    Reactions & Quotes<\/h2>\n

    The lead investigator at the Cleveland Clinic, who cautions that findings are preliminary, highlights both opportunity and uncertainty around the approach.<\/p>\n

    \n

    “The fact that there is already pretty extensive experience with this CAR\u2011T approach in cancer gives us a big head start, but we must be cautious \u2014 these are early exploratory studies and we don\u2019t yet know if the therapy will succeed in MS.”<\/p>\n

    Dr. Jeffrey Cohen, Cleveland Clinic (experimental therapeutics)<\/cite><\/p><\/blockquote>\n

    Some MS specialists urge restraint, noting that anti\u2011B cell antibodies already reduce inflammation in many patients despite limited brain penetration.<\/p>\n

    \n

    “I\u2019m hesitant to believe CAR\u2011T will meaningfully change outcomes in progressive MS; inflammation is only part of the problem and we need strategies that protect and repair the brain.”<\/p>\n

    Dr. Rhonda Voskuhl, UCLA Multiple Sclerosis Program (clinical expert)<\/cite><\/p><\/blockquote>\n

    Other clinicians emphasize the value of further study even if CAR\u2011T does not fully reverse damage.<\/p>\n

    \n

    “Even if CAR\u2011T doesn\u2019t work as hoped, the immune biology we learn from these trials will be important for designing better treatments.”<\/p>\n

    Dr. Enrique Alvarez, Rocky Mountain MS Center (clinical director)<\/cite><\/p><\/blockquote>\n

    \n